샘플 요청 목록

 카트 문의
시장보고서
상품코드
1777608

세계의 돼지 백신 시장

Swine Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 398 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 돼지 백신 시장은 2030년까지 21억 달러에 이를 전망

2024년에 17억 달러로 추정되는 돼지 백신 세계 시장은 2024-2030년간 CAGR 3.7%로 성장하여 2030년에는 21억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 불활성화는 CAGR4.1%를 나타내고, 분석 기간 종료까지 13억 달러에 이를 것으로 예측됩니다. 수정/불활성화 생균 부문의 성장률은 분석 기간중 CAGR 2.7%로 추정됩니다.

미국 시장은 추정 4억 6,260만 달러, 중국은 CAGR6.9%를 보일 것으로 예측

미국의 돼지 백신 시장은 2024년에 4억 6,260만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년 CAGR 6.9%로 성장하여 2030년까지 4억 2,440만 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.4%와 2.8%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.1%를 나타낼 전망입니다.

세계의 돼지 백신 시장 - 주요 동향과 촉진요인 정리

왜 백신이 현대 양돈장 관리의 중심이 되고 있는가?

세계 양돈 산업은 신종 전염병과 바이오 보안 위협부터 항생제 감축 압력 증가에 이르기까지 다양한 문제에 직면해 있습니다. 이러한 상황 속에서 백신은 예방적 선택에서 가축군 건강 전략의 기초가 되는 요소로 진화해 왔습니다. 아프리카돼지열병(ASF), 돼지생식기호흡기증후군(PRRS), 고전적 돼지열병(CSF)과 같은 질병이 주요 돼지고기 생산 지역 전체에 치명적인 손실을 초래함에 따라, 생산자들은 위험을 줄이고 생산의 연속성을 보호하기 위해 백신 접종 프로토콜에 점점 더 의존하고 있습니다. 하고 있습니다. 백신은 풍토병을 억제하는 데 도움이 될 뿐만 아니라 이차 감염의 발생률을 낮추고 항균제의 전체 사용량을 줄일 수 있습니다. 또한, 양돈의 규모와 밀도가 높아짐에 따라 급속한 질병 전파의 위협이 증가하고 있으며, 이환율과 폐사율을 최소화하기 위해 정기적인 예방접종이 필수적입니다. 그 결과, 백신 접종은 더 이상 비용으로 간주되지 않고, 돈군의 회복력, 생산성 및 장기적인 수익성을 높이기 위한 투자로 간주되어 전 세계적으로 돼지 건강 관리의 핵심을 담당하고 있습니다.

새로운 백신 기술은 돼지 질병 예방에 어떤 변화를 가져오고 있는가?

기술 혁신은 돼지 백신의 개발 및 공급을 재구성하여 더 빠르고, 더 효과적이며, 더 타겟팅된 예방접종 전략을 가능하게 하고 있습니다. 재조합 DNA 기술, 바이러스 벡터 플랫폼, RNA 기반 백신의 발전은 부작용을 줄이면서 더 넓은 예방 효과를 제공하는 차세대 솔루션의 길을 열어주고 있습니다. 감염동물과 백신 접종 동물을 구분하는 백신인 DIVA 백신은 무병 인증을 유지하면서 서바이벌을 지원하기 때문에 특히 CSF와 같이 무역에 영향을 미치는 질병에서 주목받고 있습니다. 또한, 백신 접종 스케줄을 간소화하고 접종 중 동물의 스트레스를 줄이기 위해 다가백신과 혼합백신이 개발되고 있습니다. 피내 투여 및 바늘을 사용하지 않는 전달 시스템은 조직 손상 및 교차 오염의 위험을 최소화하여 동물 복지와 바이오 보안을 모두 향상시킵니다. 진단 연동형 백신 접종(DLV) 시스템도 시범적으로 도입되어 실시간 질병 진단과 백신 접종 결정을 통합하여 접종 시기와 효과를 개선하고 있습니다. 이러한 기술 혁신은 생산자가 전체 소군에서 더 높은 면역 수준을 달성하고, 노동 시간을 단축하며, 백신 접종 프로그램을 진화하는 질병 압력에 맞게 조정하는 데 도움이 되고 있습니다.

규제, 무역 역학, 바이오 보안 의무는 어떤 역할을 하는가?

돼지 백신 시장은 규제 프레임워크, 국제 무역 상황, 진화하는 바이오 보안 의무의 영향을 많이 받습니다. 많은 국가에서 백신의 사용은 USDA, EMA, CFDA 등 정부 당국에 의해 엄격하게 규제되고 있으며, 안전성, 유효성 및 규정 준수를 보장하기 위해 엄격한 승인 경로가 마련되어 있습니다. 세계 돼지고기 교역, 특히 아시아, 유럽, 북미, 남미 간 교역이 지속적으로 확대됨에 따라 질병 관리는 수출 자격의 필수 조건이 되고 있습니다. 효과적인 백신 접종 프로그램과 무병 상태를 증명할 수 있는 국가는 시장 접근과 무역 파트너를 유지하는 데 큰 이점을 가지고 있습니다. 이에 따라 정부는 특히 ASF나 구제역(FMD)과 같은 신고 가능한 국경 간 질병에 대한 대규모 백신 접종 캠페인에 자금을 지원하게 되었습니다. 또한, 업계가 주도하는 인증 및 소매업체 조달 요건은 동물 복지 및 지속가능성에 대한 노력의 일환으로 생산자들이 종합적인 백신 접종 기록을 유지하도록 장려하고 있습니다. 바이오 보안은 양돈업의 핵심 개념으로 자리 잡았으며, 특히 최근 발생한 질병을 고려할 때 백신은 종합적인 질병 예방 프로토콜의 첫 번째 방어선으로 간주되고 있습니다. 규제, 무역 및 농장 수준의 기대치가 일치함에 따라 최신 양돈 생산의 방어 수단이자 준수 요건으로서 백신 도입이 강화되고 있습니다.

돼지 백신 시장의 강력한 성장 원동력은?

돼지 백신 시장의 성장은 역학 동향, 기술 발전, 생산 시스템 진화, 세계 정책 조정 등 다양한 요인이 복합적으로 작용하여 이루어집니다. PRRS, 폐렴 마이코플라즈마, ASF와 같은 전염병 및 신흥 질병의 유행이 증가함에 따라 예방 백신과 긴급 백신에 대한 지속적인 수요가 발생하고 있습니다. 보조제, 항원 탐색, 백신 전달 분야의 기술 발전은 제품의 가용성과 효능을 확장하고, 새로운 기술 혁신 분야를 개발하고 있습니다. 규제 금지, 수출 기준, 소비자 의식에 힘입어 항생제에서 백신으로 전환하면서 주요 질병 관리 전략으로서 백신의 중요성이 커지고 있습니다. 생산 수준에서 양돈의 강화와 대규모 경영의 통합으로 가축군 건강 관리의 경제적 가치가 높아지고 있으며, 백신은 위험 감소의 핵심적인 역할을 하고 있습니다. 이와 병행하여 아시아, 라틴아메리카, 아프리카에서는 민관 파트너와 정부가 자금을 지원하는 예방접종 이니셔티브가 상업 및 소규모 농가 모두에 백신을 도입할 수 있도록 지원하고 있습니다. 콜드체인 물류의 개선, 수의학 정보학의 부상, 정밀 축산 플랫폼에 백신 접종의 통합은 접근성과 영향력을 더욱 향상시키고 있습니다. 이러한 시장 성장 촉진요인들이 결합되어 돼지 백신 시장은 전 세계적으로 지속 가능하고 확장 가능하며 생물학적으로 안전한 돼지고기 생산의 중요한 축으로 자리매김하고 있습니다.

부문

제품 유형(불활성화, 약독화, 기타), 질병 유형(돼지 인플루엔자, 돼지 열병, 돼지 파보바이러스, 돼지 서코바이러스 2형, M.Hyo, 액티노바실러스 폐렴, PRRS, 구제역, 광견병, PEDV, 기타), 투여 경로(주사제, 경비제, 경구제)

조사 대상 기업 예

  • Aptimmune Biologics
  • Baseimmune
  • Biogenesis Bago
  • Boehringer Ingelheim International GmbH
  • Cambridge Technologies
  • Ceva Sante Animale
  • Codagenix
  • Elanco Animal Health Incorporated
  • Genvax Technologies
  • HIPRA
  • Indian Immunologicals Limited
  • iBio
  • KM Biologics
  • Merck & Co., Inc.
  • Phibro Animal Health Corporation
  • Ring Biotechnology Co Ltd.
  • Sequent Scientific Limited
  • Serum Institute of India
  • Vaxxinova International BV
  • Vetoquinol S.A.
  • Virbac
  • ViroVet

AI 통합

우리는 검증 된 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.01

Global Swine Vaccines Market to Reach US$2.1 Billion by 2030

The global market for Swine Vaccines estimated at US$1.7 Billion in the year 2024, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Inactivated, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the Modified / Attenuated Live segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$462.6 Million While China is Forecast to Grow at 6.9% CAGR

The Swine Vaccines market in the U.S. is estimated at US$462.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$424.4 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Swine Vaccines Market - Key Trends & Drivers Summarized

Why Are Vaccines Becoming Central to Modern Swine Herd Management?

The global swine industry is confronting mounting challenges ranging from emerging infectious diseases and biosecurity threats to growing pressure for antibiotic reduction. In this context, vaccines have evolved from a preventive option to a foundational component of herd health strategies. With disease outbreaks like African Swine Fever (ASF), Porcine Reproductive and Respiratory Syndrome (PRRS), and Classical Swine Fever (CSF) causing devastating losses across major pork-producing regions, producers are increasingly leaning on vaccination protocols to mitigate risks and protect production continuity. Vaccines not only help control endemic diseases but also reduce the incidence of secondary infections, lowering the overall use of antimicrobials-a key goal in the global fight against antimicrobial resistance (AMR). Moreover, as pig farming scales up in intensity and density, the threat of rapid disease transmission grows, making routine immunization essential to minimize morbidity and mortality. As a result, vaccination is no longer seen as a cost but rather an investment in herd resilience, productivity, and long-term profitability, securing its place at the core of swine health management worldwide.

How Are New Vaccine Technologies Transforming Swine Disease Prevention?

Technological innovation is reshaping the development and delivery of swine vaccines, enabling faster, more effective, and more targeted immunization strategies. Advances in recombinant DNA technologies, viral vector platforms, and RNA-based vaccines are paving the way for next-generation solutions that offer broader protection with fewer side effects. Marker (DIVA) vaccines-those that differentiate infected from vaccinated animals-are gaining prominence, particularly for diseases with trade implications like CSF, as they support surveillance while maintaining disease-free certifications. Additionally, multivalent and combination vaccines are being developed to simplify vaccination schedules and reduce animal stress during administration. Intradermal and needle-free delivery systems are improving both animal welfare and biosecurity by minimizing tissue damage and cross-contamination risks. Diagnostic-linked vaccination (DLV) systems are also being piloted, integrating real-time disease diagnostics with vaccination decisions to improve timing and efficacy. These innovations are helping producers achieve higher immunity levels across herds, reduce labor time, and tailor vaccination programs to evolving disease pressures-marking a new era in data-driven, precision veterinary medicine.

What Role Do Regulations, Trade Dynamics, and Biosecurity Mandates Play?

The swine vaccines market is deeply influenced by regulatory frameworks, international trade conditions, and evolving biosecurity mandates. In many countries, vaccine use is closely regulated by government authorities such as the USDA, EMA, or CFDA, with strict approval pathways to ensure safety, efficacy, and compliance. As global pork trade continues to grow, especially between Asia, Europe, and the Americas, disease control becomes a prerequisite for export eligibility. Countries that can demonstrate effective vaccination programs and disease-free status have a significant advantage in maintaining market access and trade partnerships. This has pushed governments to fund mass vaccination campaigns, particularly for notifiable and transboundary diseases like ASF and Foot-and-Mouth Disease (FMD). Additionally, industry-driven certifications and retailer sourcing requirements are encouraging producers to maintain comprehensive vaccination records as part of animal welfare and sustainability commitments. Biosecurity has become a central tenet in swine farming, especially in light of recent outbreaks, and vaccines are now viewed as the first line of defense within integrated disease prevention protocols. The alignment of regulatory, trade, and farm-level expectations is reinforcing vaccine adoption as both a protective measure and a compliance requirement in modern swine production.

What’s Driving the Strong Growth in the Swine Vaccines Market?

The growth in the swine vaccines market is driven by a confluence of factors that span epidemiological trends, technological advancement, production system evolution, and global policy alignment. The rising prevalence of infectious and emerging diseases-such as PRRS, Mycoplasma hyopneumoniae, and ASF-is creating sustained demand for both prophylactic and emergency-use vaccines. Technological progress in adjuvant formulations, antigen discovery, and vaccine delivery is broadening product availability and effectiveness, opening up new segments for innovation. The global shift away from antibiotics-driven by regulatory bans, export standards, and consumer awareness-is amplifying the importance of vaccines as a primary disease control strategy. At the production level, intensification of swine farming and the consolidation of large-scale operations are increasing the economic value of herd health management, with vaccines playing a central role in risk mitigation. In parallel, public-private partnerships and government-funded immunization initiatives in Asia, Latin America, and Africa are supporting vaccine deployment in both commercial and smallholder systems. Improved cold chain logistics, the rise of veterinary health informatics, and the integration of vaccination into precision livestock farming platforms are further enhancing accessibility and impact. Together, these drivers are propelling the swine vaccines market forward-solidifying its position as a critical pillar of sustainable, scalable, and biosecure pork production worldwide.

SCOPE OF STUDY:

The report analyzes the Swine Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Inactivated, Modified / Attenuated Live, Others); Disease Type (Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo, Actinobacillus Pleuropneumonia, PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Others); Administration Route (Injectables, Intranasal, Oral)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Aptimmune Biologics
  • Baseimmune
  • Biogenesis Bago
  • Boehringer Ingelheim International GmbH
  • Cambridge Technologies
  • Ceva Sante Animale
  • Codagenix
  • Elanco Animal Health Incorporated
  • Genvax Technologies
  • HIPRA
  • Indian Immunologicals Limited
  • iBio
  • KM Biologics
  • Merck & Co., Inc.
  • Phibro Animal Health Corporation
  • Ring Biotechnology Co Ltd.
  • Sequent Scientific Limited
  • Serum Institute of India
  • Vaxxinova International BV
  • Vetoquinol S.A.
  • Virbac
  • ViroVet

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Swine Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Endemic and Emerging Swine Diseases Throws the Spotlight on Prophylactic Vaccination Strategies
    • Growing Concerns Over Antibiotic Resistance Strengthen the Business Case for Preventive Vaccination in Swine Herds
    • Expansion of Intensive Pig Farming Operations Propels Demand for Scalable and Efficient Vaccine Protocols
    • Increased Awareness of Zoonotic Disease Risks Drives Adoption of Biosecurity-Linked Vaccination Programs
    • Technological Advancements in Vaccine Formulation and Delivery Generate Demand for Next-Generation Swine Vaccines
    • Integration of Precision Livestock Tools with Veterinary Protocols Accelerates Demand for Data-Driven Vaccination Management
    • Surge in Global Pork Consumption Expands the Addressable Market for Herd Immunization Solutions
    • Emergence of Novel Pathogen Strains and Mutations Creates Ongoing Challenges for Vaccine Efficacy and Coverage
    • Government-Led Mass Vaccination Programs and Subsidies Sustain Growth in Developing and Disease-Prone Regions
    • Digital Health Monitoring and Traceability Systems Enhance Compliance with Vaccination Schedules and Records
    • Rising Demand for Customized and Region-Specific Vaccines Drives Collaboration Between Biotech Firms and Local Producers
    • Improvements in Cold Chain Infrastructure and Logistics Facilitate Wider Access to Thermo-Sensitive Vaccine Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Swine Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Swine Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Swine Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Swine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Modified / Attenuated Live by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Modified / Attenuated Live by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Modified / Attenuated Live by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for PRRS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for PRRS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for PRRS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Foot & Mouth Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Foot & Mouth Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Foot & Mouth Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pseudorabies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pseudorabies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pseudorabies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for PEDV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for PEDV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for PEDV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Swine Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Swine Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Swine Influenza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Classical Swine Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Classical Swine Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Classical Swine Fever by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Porcine Parvovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Porcine Parvovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Porcine Parvovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Porcine Circovirus Type 2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Porcine Circovirus Type 2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Porcine Circovirus Type 2 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for M.Hyo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for M.Hyo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for M.Hyo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Actinobacillus Pleuropneumonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Actinobacillus Pleuropneumonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Actinobacillus Pleuropneumonia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: World 15-Year Perspective for Intranasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 56: USA Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • JAPAN
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • CHINA
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • EUROPE
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Swine Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Swine Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Swine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • FRANCE
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • GERMANY
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: UK 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: UK 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 140: Spain Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Spain Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Spain 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Spain 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Spain 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 149: Russia Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Russia Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Russia 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 152: Russia Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Russia Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Russia 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Russia 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Swine Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 15-Year Perspective for Swine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 179: Australia Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Australia Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Australia 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 182: Australia Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Australia Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Australia 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 185: Australia Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Australia Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Australia 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • INDIA
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 188: India Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: India Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: India 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 191: India Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: India Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: India 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 194: India Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: India Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: India 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 197: South Korea Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: South Korea Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: South Korea 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 200: South Korea Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: South Korea Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: South Korea 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 203: South Korea Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: South Korea Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: South Korea 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Asia-Pacific Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Asia-Pacific Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Asia-Pacific 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 212: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Asia-Pacific Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Asia-Pacific 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Swine Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Latin America 15-Year Perspective for Swine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 218: Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Latin America Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Latin America 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 221: Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Latin America Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Latin America 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 224: Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Latin America Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Latin America 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 227: Argentina Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Argentina Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Argentina 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 230: Argentina Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Argentina Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Argentina 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 233: Argentina Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Argentina Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Argentina 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 236: Brazil Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Brazil Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Brazil 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 239: Brazil Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Brazil Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Brazil 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 242: Brazil Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Brazil Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Brazil 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 245: Mexico Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Mexico Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Mexico 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 248: Mexico Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Mexico Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Mexico 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 251: Mexico Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Mexico Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Mexico 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Rest of Latin America Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Rest of Latin America 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 257: Rest of Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Latin America Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Rest of Latin America 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 260: Rest of Latin America Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Latin America Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Rest of Latin America 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Swine Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Middle East 15-Year Perspective for Swine Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 266: Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Middle East Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Middle East 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 269: Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Middle East Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Middle East 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 272: Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Middle East Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Middle East 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 275: Iran Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Iran Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Iran 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 278: Iran Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Iran Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Iran 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 281: Iran Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Iran Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Iran 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 284: Israel Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Israel Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Israel 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 287: Israel Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Israel Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Israel 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 290: Israel Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Israel Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Israel 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Saudi Arabia Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Saudi Arabia 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 296: Saudi Arabia Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Saudi Arabia Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Saudi Arabia 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 299: Saudi Arabia Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Saudi Arabia Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Saudi Arabia 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 302: UAE Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: UAE Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: UAE 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 305: UAE Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: UAE Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: UAE 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 308: UAE Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: UAE Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: UAE 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Middle East Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Middle East 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Middle East Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Middle East 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 317: Rest of Middle East Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Rest of Middle East Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Rest of Middle East 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030
  • AFRICA
    • Swine Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 320: Africa Recent Past, Current & Future Analysis for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Africa Historic Review for Swine Vaccines by Product - Inactivated, Modified / Attenuated Live and Other Products Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Africa 15-Year Perspective for Swine Vaccines by Product - Percentage Breakdown of Value Sales for Inactivated, Modified / Attenuated Live and Other Products for the Years 2015, 2025 & 2030
    • TABLE 323: Africa Recent Past, Current & Future Analysis for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Africa Historic Review for Swine Vaccines by Disease Type - PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Africa 15-Year Perspective for Swine Vaccines by Disease Type - Percentage Breakdown of Value Sales for PRRS, Foot & Mouth Disease, Pseudorabies, PEDV, Other Disease Types, Swine Influenza, Classical Swine Fever, Porcine Parvovirus, Porcine Circovirus Type 2, M.Hyo and Actinobacillus Pleuropneumonia for the Years 2015, 2025 & 2030
    • TABLE 326: Africa Recent Past, Current & Future Analysis for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Africa Historic Review for Swine Vaccines by Administration Route - Injectables, Intranasal and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Africa 15-Year Perspective for Swine Vaccines by Administration Route - Percentage Breakdown of Value Sales for Injectables, Intranasal and Oral for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제